테라젠이텍스
Financials
Valuation Metrics
테라젠이텍스's Market Cap is ₩734B. At end of 2025 it was ₩1159B. Ranked #1437 of 2,410 in KR market (top 60%), #817 of 1,631 on KOSDAQ (top 50%), #159 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.37B KRW | KR#1,437/2,410 Sec#159/231 |
| Revenue | 275.36B KRW | KR#872/2,410 Sec#42/231 |
| Net Income | 2.83B KRW | KR#1,358/2,410 Sec#95/231 |
| Total Assets | 241.17B KRW | KR#1,166/2,410 Sec#81/231 |
| Net Assets | 143.98B KRW | KR#1,166/2,410 Sec#84/231 |
| Employees | 214 | KR#1,046/2,410 Sec#86/231 |
| Value | ||
| P/E | 25.96x | KR#1,286/2,410 Sec#79/231 |
| P/B | 0.51x | KR#885/2,410 Sec#44/231 |
| P/S | 0.27x | KR#565/2,410 Sec#12/231 |
| EV/EBITDA | 10.63x | KR#695/2,410 Sec#34/231 |
| FCF Yield | 11.44% | KR#585/2,410 Sec#19/231 |
| Profitability | ||
| ROE | 1.96% | KR#1,412/2,410 Sec#97/231 |
| ROA | 1.17% | KR#1,378/2,410 Sec#99/231 |
| Op. Margin | 3.91% | KR#1,103/2,410 Sec#79/231 |
| Revenue Growth | 6.13% | KR#1,122/2,410 Sec#110/231 |
| Financial Health | ||
| Debt Ratio | 67.50% | KR#1,186/2,410 Sec#143/231 |
| Total Debt | 80.74B KRW | KR#796/2,410 Sec#49/231 |
| FCF | 8.40B KRW | KR#760/2,410 Sec#42/231 |
| Cash | 39.52B KRW | KR#862/2,410 Sec#54/231 |
| Current Ratio | 1.78x | KR#985/2,410 Sec#109/231 |
| Net Debt/EBITDA | 3.82x | KR#953/2,410 Sec#72/231 |
| Dividend | ||
| Div. Yield | 0.40% | KR#1,303/2,410 Sec#82/231 |
| Performance | ||
| 1Y Return | -21.57% | KR#1,226/2,410 Sec#89/231 |
| 1M Return | -11.70% | KR#1,494/2,410 Sec#152/231 |
| From 52W High | -42.36% | KR#867/2,410 Sec#60/231 |
| 1Y MDD | -43.05% | KR#676/2,410 Sec#46/231 |
| Trading | ||
| Volume | 36,713 shares | KR#1,535/2,410 Sec#157/231 |
| Trading Value | 73.1M KRW | KR#1,838/2,410 Sec#192/231 |
| Foreign Own. | 2.27% | KR#1,533/2,410 Sec#145/231 |
| Per Share | ||
| EPS | 77 KRW | KR#1,468/2,410 Sec#101/231 |
| BPS | 3,925 KRW | KR#1,697/2,410 Sec#125/231 |
Company Info
Theragen Etex, established in 1990 and listed on KOSDAQ in 2004, adopted its current name after merging with Etex Pharmaceutical in 2010. The company primarily manufactures and sells specialized and general medicines and provides genome sequencing services, with Leadfarm, Theragen Healthcare, and Theragen Bio as subsidiaries. Theragen Etex focuses on new drug R&D, DNA sequencing, and RNA variant genome analysis to address future medical changes, and is pursuing global market expansion through its Chinese local subsidiary. It is headquartered in Ansan-si, Gyeonggi-do.